Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder

[1]  F. Fregni,et al.  Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: Implications for the serotonergic system , 2013, European Neuropsychopharmacology.

[2]  A. Serretti,et al.  Pharmacogenetics in major depression: A comprehensive meta-analysis , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  D. Rujescu,et al.  No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[4]  G. Andersson,et al.  The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta‐analysis of direct comparisons , 2013, World psychiatry : official journal of the World Psychiatric Association.

[5]  L. Lazzeroni,et al.  BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression , 2013, Pharmacogenetics and genomics.

[6]  A. Serretti,et al.  No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression , 2013, Psychiatry investigation.

[7]  R. Hen,et al.  BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities , 2013, Translational Psychiatry.

[8]  S. Kaneko,et al.  DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. , 2012, Journal of clinical psychopharmacology.

[9]  Kangguang Lin,et al.  Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. , 2012, Psychiatric genetics.

[10]  E. Frank,et al.  The role of personality pathology in depression treatment outcome with psychotherapy and pharmacotherapy. , 2012, Journal of Consulting and Clinical Psychology.

[11]  A. Serretti,et al.  Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder , 2012, Psychiatry Research.

[12]  J. Unützer,et al.  Strategies to improve the management of depression in primary care. , 2012, Primary care.

[13]  Evangelos Evangelou,et al.  TPH2 Gene Polymorphisms and Major Depression – A Meta-Analysis , 2012, PloS one.

[14]  A. Serretti,et al.  Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy , 2012, European Neuropsychopharmacology.

[15]  F. Lohoff,et al.  Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. , 2012, Pharmacogenomics.

[16]  Yonggui Yuan,et al.  Tryptophan hydroxylase 2 gene is associated with major depressive disorder in a female Chinese population. , 2011, Journal of affective disorders.

[17]  A. Serretti,et al.  Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia , 2011, Psychiatry Research.

[18]  Edoardo Spina,et al.  Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism , 2011, Expert opinion on drug metabolism & toxicology.

[19]  P. Deyn,et al.  The kynurenine pathway in major depression: Haplotype analysis of three related functional candidate genes , 2011, Psychiatry Research.

[20]  R. Yoshimura,et al.  The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  R. Elliott,et al.  The CREB1-BDNF-NTRK2 Pathway in Depression: Multiple Gene-Cognition-Environment Interactions , 2011, Biological Psychiatry.

[22]  A. Serretti,et al.  Pharmacogenetics of antidepressant response. , 2011, Journal of psychiatry & neuroscience : JPN.

[23]  Y. Lecrubier,et al.  Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder , 2011, International clinical psychopharmacology.

[24]  A. Serretti,et al.  Pharmacogenetics of Antidepressants , 2010, Front. Pharmacol..

[25]  S. Kim,et al.  Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression , 2010, Journal of psychopharmacology.

[26]  P. Rucci,et al.  Depression in Primary care: Interpersonal Counseling vs Selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design , 2010, BMC psychiatry.

[27]  D. Ye,et al.  Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder , 2010, European Neuropsychopharmacology.

[28]  C. Bouchard,et al.  CREB1 Is a Strong Genetic Predictor of the Variation in Exercise Heart Rate Response to Regular Exercise: The HERITAGE Family Study , 2010, Circulation. Cardiovascular genetics.

[29]  A. Serretti,et al.  Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.

[30]  B. Franke,et al.  Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity , 2010, Molecular Psychiatry.

[31]  N. Akarsu,et al.  The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels , 2010, Brain Research Bulletin.

[32]  T. Vahlberg,et al.  The outcomes of interpersonal counselling on depressive symptoms and distress after myocardial infarction , 2010, Nordic journal of psychiatry.

[33]  V. Vaccarino,et al.  Serotonin Transporter Gene, Depressive Symptoms, and Interleukin-6 , 2009, Circulation. Cardiovascular genetics.

[34]  N. Wray,et al.  Accurate, Large-Scale Genotyping of 5HTTLPR and Flanking Single Nucleotide Polymorphisms in an Association Study of Depression, Anxiety, and Personality Measures , 2009, Biological Psychiatry.

[35]  T. Lehtimäki,et al.  5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression , 2009, Neuroreport.

[36]  R. Yoshimura,et al.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[37]  S. Tsai,et al.  Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  M. Wong,et al.  Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. , 2009, Archives of general psychiatry.

[39]  J. Aldenhoff,et al.  Changes in CREB Phosphorylation and BDNF Plasma Levels during Psychotherapy of Depression , 2009, Psychotherapy and Psychosomatics.

[40]  F. McMahon,et al.  Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. , 2009, The international journal of neuropsychopharmacology.

[41]  D. Blackwood,et al.  Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy , 2009, The Pharmacogenomics Journal.

[42]  J. Brockmöller,et al.  Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment , 2008, Pharmacogenetics and genomics.

[43]  M. Åsberg,et al.  The tryptophan hydroxylase (TPH) 2 gene unlike TPH-1 exhibits no association with stress-induced depression. , 2008, Journal of affective disorders.

[44]  J. Mann,et al.  No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. , 2008, Journal of affective disorders.

[45]  G. Rosoklija,et al.  Genetic architecture of the human tryptophan hydroxylase 2 Gene: existence of neural isoforms and relevance for major depression , 2008, Molecular Psychiatry.

[46]  D. Blackwood,et al.  A splice site polymorphism in the G-protein &bgr; subunit influences antidepressant efficacy in depression , 2007, Pharmacogenetics and genomics.

[47]  K. Sleegers,et al.  Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. , 2006, Archives of General Psychiatry.

[48]  H. Corrêa,et al.  Genotyping of the G1463A (Arg441His) TPH2 polymorphism in a geriatric population of patients with major depression , 2006, Molecular Psychiatry.

[49]  T. Bourgeron,et al.  No Human Tryptophan Hydroxylase-2 Gene R441H Mutation in a Large Cohort of Psychiatric Patients and Control Subjects , 2006, Biological Psychiatry.

[50]  D. Goldman,et al.  Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. , 2005, Archives of general psychiatry.

[51]  L. Marangell,et al.  Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance , 2005, Molecular Psychiatry.

[52]  F. Taneli,et al.  The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  David A. Schwartz,et al.  Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression , 2005, Neuron.

[54]  H. Möller,et al.  SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression , 2004, Molecular Psychiatry.

[55]  J. Knowles,et al.  Investigation of serotonin-related genes in antidepressant response , 2004, Molecular Psychiatry.

[56]  F. Mazzi,et al.  Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.

[57]  S. Tsai,et al.  Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[58]  M. Egan,et al.  The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.

[59]  J. Aldenhoff,et al.  Changes in CREB-phosphorylation during recovery from major depression. , 2002, Journal of psychiatric research.

[60]  D. Ginty,et al.  Function and Regulation of CREB Family Transcription Factors in the Nervous System , 2002, Neuron.

[61]  G. Zubenko,et al.  Genome survey for susceptibility loci for recurrent, early-onset major depression: results at 10cM resolution. , 2002, American journal of medical genetics.

[62]  P. Zwanzger,et al.  Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression , 2001, European Neuropsychopharmacology.

[63]  Marc Montminy,et al.  Transcriptional regulation by the phosphorylation-dependent factor CREB , 2001, Nature Reviews Molecular Cell Biology.

[64]  M. Weissman,et al.  A comparative study of venlafaxine with a focused education and psychotherapy program versus venlafaxine alone in the treatment of depression in general practice , 2001, Human psychopharmacology.

[65]  H. Vedder,et al.  Cytokine Production and Treatment Response in Major Depressive Disorder , 2000, Neuropsychopharmacology.

[66]  M. Takigawa,et al.  Serotonin-induced platelet intracellular Ca2+ responses in untreated depressed patients and imipramine responders in remission , 1999, Biological Psychiatry.

[67]  H. Manji,et al.  A Naturally Occurring Amino Acid Substitution of the Human Serotonin 5‐HT2A Receptor Influences Amplitude and Timing of Intracellular Calcium Mobilization , 1997, Journal of neurochemistry.

[68]  Paul J. Harrison,et al.  The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain , 1995, Brain Research.

[69]  A. Serretti,et al.  A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. , 2011, Journal of affective disorders.

[70]  J. Bauer,et al.  Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[71]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[72]  I. Kusumi,et al.  Serotonin-induced platelet intracellular calcium mobilization in depressed patients , 2005, Psychopharmacology.

[73]  G. Zubenko,et al.  D2S2944 identifies a likely susceptibility locus for recurrent, early-onset, major depression in women , 2002, Molecular Psychiatry.